Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sangam Health Care's...

    Sangam Health Care's former promoter settles case with SEBI, pays Rs 48 Lakh

    Written by Ruby Khatun Khatun Published On 2018-07-04T10:00:52+05:30  |  Updated On 4 July 2018 10:00 AM IST
    Sangam Health Cares former promoter settles case with SEBI, pays Rs 48 Lakh

    New Delhi: Markets regulator SEBI has settled a case related to alleged disclosure lapses by an erstwhile promoter of pharmaceutical firm Sangam Health Care Products after he paid over Rs 48 lakh towards settlement.


    The regulator had initiated adjudication proceedings against L S Patil (former promoter of Sangam Health Care) for allegedly not complying with disclosure norms as required under SAST (Substantial Acquisition of Shares and Takeovers) Regulations and PIT (Prohibition of Insider Trading) Regulations.


    In an order dated June 29, Sebi noted that last month Patil remitted the settlement amount of Rs 48.26 lakh in respect of the alleged violations, following which the regulator disposed of the proceedings against him.


    The former promoter of Sangam Health Care had submitted an application to settle the proceedings initiated against him by the Securities and Exchange Board of India (Sebi), the regulator said.


    The regulator's High Powered Advisory Committee had recommended the settlement of the case on payment of Rs 48.26 lakh by Patil. The recommendation was also accepted by the panel of Whole Time Members of Sebi.


    This settlement order "disposes of" the adjudication proceedings in respect of Patil, the regulator said.


    However, Sebi noted if any representation made by Patil in the settlement proceedings is subsequently found to be untrue, the regulator would initiate proceedings against him.


    In a separate order dated June 29, Sebi also settled a case related to alleged violation of PIT Regulations with Polaris Software Lab, now known as Polaris Consulting and Services, after the firm paid Rs 6.80 lakh towards settlement.

    casedisclosure lapseserstwhile promoterformer promoterL S Patilpharmaceutical firmPITPolaris Software LabProhibition of Insider TradingSangam Health CareSASTSEBISecurities and Exchange Board of IndiaSubstantial Acquisition of Shares and Takeoversviolations
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok